Jose J G Marin

List of Publications by Year in Descending Order

243 papers	8,273 citations	46 h-index	78 g-index
263 ext. papers	10,107 ext. citations	6 avg, IF	5.82 L-index

#	Paper	IF	Citations
243	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. *Journal of Hepatology*, **2021**,	13.4	10
242	Impact of alternative splicing on mechanisms of resistance to anticancer drugs. *Biochemical Pharmacology*, **2021**, 193, 114810	6	4
241	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. *Aging*, **2021**, 13, 23416-23434	5.6	1
240	Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. *Cancers*, **2021**, 13,	6.6	1
239	Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. *Hepatology*, **2021**, 73, 2380-2396	11.2	3
238	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. *Cancers*, **2021**, 13,	6.6	3
237	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. *Cell Death and Disease*, **2021**, 12, 555	9.8	2
236	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. *JHEP Reports*, **2021**, 3, 100276	10.3	0
235	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. *Journal of Hepatology*, **2021**, 74, 1429-1441	13.4	10
234	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. *Hepatology*, **2021**, 73, 186-203	11.2	1
233	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. *Expert Opinion on Investigational Drugs*, **2021**, 30, 377-388	5.9	2
232	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. *Seminars in Liver Disease*, **2021**,	7.3	2
231	Gene supplementation of in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis. *Molecular Therapy - Methods and Clinical Development*, **2021**, 22, 210-221	6.4	1
230	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. *Molecular Metabolism*, **2021**, 53, 101275	8.8	2
229	Impact of Alternative Splicing Variants on Liver Cancer Biology.. *Cancers*, **2021**, 14,	6.6	1
228	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. *Cancers*, **2020**, 12,	6.6	1
227	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. *Cancers*, **2020**, 12,	6.6	11

226	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. *Cells*, **2020**, 9,	7.9	34
225	JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 16492-16499	11.5	22
224	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 557-588	24.2	355
223	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. *Cancers*, **2020**, 12,	6.6	15
222	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. *Cancers*, **2020**, 12,	6.6	37
221	Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma. *Cells*, **2020**, 9,	7.9	4
220	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165687	6.9	5
219	Role of Genetic Variations in the Hepatic Handling of Drugs. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
218	Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. *Biochemical Pharmacology*, **2020**, 171, 113682	6	3
217	MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. *Hepatology*, **2020**, 72, 949-964	11.2	11
216	Liver and gastrointestinal cancers **2020**, 197-250		0
215	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. *British Journal of Cancer*, **2020**, 123, 1047-1059	8.7	23
214	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl-Induced Liver Fibrosis. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
213	Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma. *Cancers*, **2020**, 12,	6.6	13
212	Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. *Cancers*, **2020**, 12,	6.6	11
211	Leishmania heme uptake involves LmFLVCRb, a novel porphyrin transporter essential for the parasite. *Cellular and Molecular Life Sciences*, **2020**, 77, 1827-1845	10.3	11
210	Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer. *Pharmacogenomics*, **2019**, 20, 957-970	2.6	0
209	Chemosensitization of hepatocellular carcinoma cells to sorafenib by Ɛcaryophyllene oxide-induced inhibition of ABC export pumps. *Archives of Toxicology*, **2019**, 93, 623-634	5.8	22

208	What "The Cancer Genome Atlas" database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. *Expert Opinion on Drug Metabolism and Toxicology*, **2019**, 15, 577-593	5.5	15
207	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. *Liver International*, **2019**, 39 Suppl 1, 43-62	7.9	32
206	Mechanisms of Anticancer Drug Resistance in Hepatoblastoma. *Cancers*, **2019**, 11,	6.6	18
205	Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. *Hepatology*, **2019**, 70, 1246-1261	11.2	30
204	Evaluation of the promiscuous component of several bacterial export pumps TolC as a biomarker for toxic pollutants in feedstuffs. *Chemico-Biological Interactions*, **2019**, 305, 195-202	5	2
203	Biopiracy versus One-World Medicine-From colonial relicts to global collaborative concepts. *Phytomedicine*, **2019**, 53, 319-331	6.5	8
202	Hepatoprotection of L., L. and L. *Antioxidants*, **2019**, 8,	7.1	9
201	Models for Understanding Resistance to Chemotherapy in Liver Cancer. *Cancers*, **2019**, 11,	6.6	17
200	Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma. **2019**, 2, 680-709		1
199	Unraveling "The Cancer Genome Atlas" information on the role of SLC transporters in anticancer drug uptake. *Expert Review of Clinical Pharmacology*, **2019**, 12, 329-341	3.8	11
198	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. *British Journal of Pharmacology*, **2019**, 176, 787-800	8.6	30
197	The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. *Hepatology*, **2019**, 69, 1632-1647	11.2	19
196	Wnt-β-catenin signalling in liver development, health and disease. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 121-136	24.2	156
195	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. *Hepatology*, **2019**, 70, 547-562	11.2	54
194	Dysregulation of autophagy in rat liver with mitochondrial DNA depletion induced by the nucleoside analogue zidovudine. *Archives of Toxicology*, **2018**, 92, 2109-2118	5.8	8
193	Molecular bases of the poor response of liver cancer to chemotherapy. *Clinics and Research in Hepatology and Gastroenterology*, **2018**, 42, 182-192	2.4	41
192	Chemoresistance and chemosensitization in cholangiocarcinoma. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2018**, 1864, 1444-1453	6.9	62
191	MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. *Hepatology*, **2018**, 67, 1420-1440	11.2	45

190	Chemoprotective Role of Vitamin C in Liver Diseases **2018**, 139-153		
189	Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. *Journal of Personalized Medicine*, **2018**, 8,	3.6	23
188	Role of the placenta in serum autotaxin elevation during maternal cholestasis. *American Journal of Physiology - Renal Physiology*, **2018**, 315, G399-G407	5.1	3
187	Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2018**, 1864, 2927-2937	6.9	11
186	Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. *Oncotarget*, **2018**, 9, 28474-28485	3.3	7
185	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2018**, 1864, 1468-1477	6.9	49
184	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. *PLoS ONE*, **2018**, 13, e0208225	3.7	1
183	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. *Journal of Hepatology*, **2017**, 67, 72-83	13.4	57
182	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. *Digestive Diseases*, **2017**, 35, 275-281	3.2	5
181	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. *Hepatology*, **2017**, 66, 1125-1143	11.2	148
180	Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. *Journal of Lipid Research*, **2017**, 58, 1903-1915	6.3	11
179	Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland. *Scientific Reports*, **2017**, 7, 7475	4.9	9
178	ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. *Journal of Hepatology*, **2017**, 66, 581-588	13.4	34
177	Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid. *PLoS ONE*, **2017**, 12, e0176504	3.7	24
176	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. *Oncotarget*, **2017**, 8, 15846-15857	3.3	32
175	Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. *Oncotarget*, **2017**, 8, 34617-34629	3.3	9
174	Further understanding of mechanisms involved in liver cancer chemoresistance. *Hepatoma Research* , **2017**, 3,	4.3	5
173	Molecular Bases of Chemoresistance in Cholangiocarcinoma. *Current Drug Targets*, **2017**, 18, 889-900	3	33

172	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. *Blood Reviews*, **2016**, 30, 55-64	11.1	23
171	Effect of pravastatin on the survival of patients with advanced gastric cancer. *Oncotarget*, **2016**, 7, 4379-84	5.5	9
170	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. *Inflammatory Bowel Diseases*, **2016**, 22, 2382-9	4.5	18
169	Mechanisms of Resistance to Chemotherapy in Gastric Cancer. *Anti-Cancer Agents in Medicinal Chemistry*, **2016**, 16, 318-34	2.2	87
168	Biodetection of potential genotoxic pollutants entering the human food chain through ashes used in livestock diets. *Food Chemistry*, **2016**, 205, 81-8	8.5	3
167	Expanding the Therapeutic Spectrum of Artemisinin: Activity Against Infectious Diseases Beyond Malaria and Novel Pharmaceutical Developments. *World Journal of Traditional Chinese Medicine*, **2016**, 2, 1-23	1	17
166	Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 9895176	6.7	20
165	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. *Hepatology*, **2016**, 63, 1287-98	11.2	56
164	Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 261-80	24.2	618
163	Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach. *Pharmacological Research*, **2016**, 113, 364-375	10.2	3
162	Lack of mitochondrial DNA impairs chemical hypoxia-induced autophagy in liver tumor cells through ROS-AMPK-ULK1 signaling dysregulation independently of HIF-1 *Free Radical Biology and Medicine*, **2016**, 101, 71-84	7.8	27
161	Protective role of biliverdin against bile acid-induced oxidative stress in liver cells. *Free Radical Biology and Medicine*, **2016**, 97, 466-477	7.8	28
160	The small intestinal mucosa acts as a rutin reservoir to extend flavonoid anti-inflammatory activity in experimental ileitis and colitis. *Journal of Functional Foods*, **2015**, 13, 117-125	5.1	16
159	Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy. *British Journal of Clinical Pharmacology*, **2015**, 79, 316-29	3.8	31
158	Treatment of paediatric cholestasis due to canalicular transport defects: yet another step forward. *Gut*, **2015**, 64, 6-8	19.2	3
157	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. *Journal of Hepatology*, **2015**, 63, 952-61	13.4	44
156	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). *Journal of Controlled Release*, **2015**, 216, 93-102	11.7	24
155	Bile Acids in Physiology, Pathology and Pharmacology. *Current Drug Metabolism*, **2015**, 17, 4-29	3.5	83

154	A GAPDH-mediated trans-nitrosylation pathway is required for feedback inhibition of bile salt synthesis in rat liver. *Gastroenterology*, **2014**, 147, 1084-93	13.3	16
153	Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. *Molecular Cancer Research*, **2014**, 12, 91-100	6.6	50
152	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. *Hepatology*, **2014**, 59, 1972-83	11.2	90
151	Rutin has intestinal antiinflammatory effects in the CD4+ CD62L+ T cell transfer model of colitis. *Pharmacological Research*, **2014**, 90, 48-57	10.2	62
150	Polycystic liver diseases: advanced insights into the molecular mechanisms. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 750-61	24.2	61
149	The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion. *Molecular Pharmaceutics*, **2014**, 11, 1856-68	5.6	23
148	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. *Gut*, **2014**, 63, 1658-67	19.2	42
147	Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2. *European Journal of Nutrition*, **2014**, 53, 401-12	5.2	11
146	The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. *Acta Pharmacologica Sinica*, **2014**, 35, 1-10	8	34
145	MicroRNAs and cholestatic liver diseases. *Current Opinion in Gastroenterology*, **2014**, 30, 303-9	3	28
144	The effect of acetaminophen on the expression of BCRP in trophoblast cells impairs the placental barrier to bile acids during maternal cholestasis. *Toxicology and Applied Pharmacology*, **2014**, 277, 77-85	4.6	23
143	Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis. *Journal of Molecular Medicine*, **2014**, 92, 359-72	5.5	18
142	Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: role of the Akt/mTOR survival pathway and Bcl-2 family proteins. *Free Radical Biology and Medicine*, **2013**, 61, 218-28	7.8	18
141	Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. *International Immunopharmacology*, **2013**, 15, 372-80	5.8	65
140	Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. *Placenta*, **2013**, 34, 810-6	3.4	24
139	Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. *Biochemical Pharmacology*, **2013**, 86, 926-39	6	66
138	FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver. *Biochemical Pharmacology*, **2013**, 85, 829-38	6	22
137	Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. *Gut*, **2013**, 62, 899-910	19.2	133

136	Maternal cholestasis during pregnancy programs metabolic disease in offspring. *Journal of Clinical Investigation*, **2013**, 123, 3172-81	15.9	72
135	Protective effects of phenolic constituents from Cytisus multiflorus, Lamium album L. and Thymus citriodorus on liver cells. *Journal of Functional Foods*, **2013**, 5, 1170-1179	5.1	28
134	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 4432-41	3.4	62
133	Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2013**, 1833, 2212-9	4.9	38
132	Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. *BioMed Research International*, **2013**, 2013, 692071	3	40
131	Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. *Hepatology*, **2013**, 58, 1065-73	11.2	102
130	Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. *Virology*, **2012**, 425, 31-9	3.6	62
129	MicroRNAs in biliary diseases. *World Journal of Gastroenterology*, **2012**, 18, 6189-96	5.6	24
128	Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. *Journal of Hepatology*, **2012**, 56, 367-73	13.4	38
127	Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. *Drug Metabolism Reviews*, **2012**, 44, 148-72	7	89
126	ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds. *Biochemical Pharmacology*, **2012**, 84, 1651-9	6	4
125	Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. *Pharmacological Research*, **2012**, 66, 419-27	10.2	7
124	Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. *Molecular Pharmaceutics*, **2012**, 9, 2565-76	5.6	48
123	No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. *Molecular Pharmaceutics*, **2012**, 9, 1693-704	5.6	66
122	Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. *Current Cancer Drug Targets*, **2012**, 12, 402-38	2.8	55
121	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. *Molecular Pharmacology*, **2012**, 81, 273-83	4.3	57
120	Plasma membrane transporters in modern liver pharmacology. *Scientifica*, **2012**, 2012, 428139	2.6	14
119	Nitric oxide mimics transcriptional and post-translational regulation during □-tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes. *Journal of Hepatology*, **2011**, 55, 133-44	13.4	27

118	Mitochondrial genome depletion dysregulates bile acid- and paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells. *British Journal of Pharmacology*, **2011**, 162, 1686-99	8.6	26
117	Characterisation of the nuclear receptors FXR, PXR and CAR in normal and cholestatic placenta. *Placenta*, **2011**, 32, 535-7	3.4	21
116	Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. *Biochemical Pharmacology*, **2011**, 81, 244-50	6	18
115	Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. *Journal of Hepato-Biliary-Pancreatic Sciences*, **2011**, 18, 740-50	2.8	16
114	Diversity of Pharmacological Properties in Chinese and European Medicinal Plants: Cytotoxicity, Antiviral and Antitrypanosomal Screening of 82 Herbal Drugs. *Diversity*, **2011**, 3, 547-580	2.5	25
113	Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. *British Journal of Nutrition*, **2011**, 106, 1814-25	3.6	25
112	A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. *Journal of Medical Genetics*, **2011**, 48, 219-25	5.8	38
111	Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. *Molecular Pharmacology*, **2011**, 79, 596-607	4.3	30
110	Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites. *Journal of Biological Chemistry*, **2010**, 285, 16504-12	5.4	48
109	Molecular bases of liver cancer refractoriness to pharmacological treatment. *Current Medicinal Chemistry*, **2010**, 17, 709-40	4.3	50
108	Strategies for overcoming chemotherapy resistance in enterohepatic tumours. *Current Molecular Medicine*, **2010**, 10, 467-85	2.5	12
107	Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. *Hepatology*, **2010**, 52, 667-77	11.2	15
106	Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. *Current Molecular Medicine*, **2009**, 9, 1108-29	2.5	31
105	Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours. *Anti-Cancer Agents in Medicinal Chemistry*, **2009**, 9, 162-84	2.2	21
104	Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. *Toxicology and Applied Pharmacology*, **2009**, 239, 21-8	4.6	14
103	In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. *Toxicology and Applied Pharmacology*, **2009**, 239, 13-20	4.6	15
102	Foetal PlatPbile acids reappear during human liver regeneration after surgery. *European Journal of Clinical Investigation*, **2009**, 39, 58-64	4.6	11
101	Bile acids: chemistry, physiology, and pathophysiology. *World Journal of Gastroenterology*, **2009**, 15, 804-16	5.6	336

100	Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs. *Frontiers in Bioscience - Landmark*, **2009**, 14, 4257-80	2.8	8
99	Excretion of biliary compounds during intrauterine life. *World Journal of Gastroenterology*, **2009**, 15, 817-28	5.6	41
98	Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds. *Liver International*, **2008**, 28, 435-54	7.9	20
97	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal unit in cholestasis during pregnancy. *Toxicology and Applied Pharmacology*, **2008**, 232, 327-36	4.6	13
96	The antiviral activities of artemisinin and artesunate. *Clinical Infectious Diseases*, **2008**, 47, 804-11	11.6	354
95	Molecular pathogenesis of intrahepatic cholestasis of pregnancy. *Expert Reviews in Molecular Medicine*, **2008**, 10, e9	6.7	68
94	Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes. *American Journal of Physiology - Renal Physiology*, **2008**, 295, G54-G62	5.1	9
93	Characterization of WIF-B9/R cells as an in vitro model with hepatocyte-like polarity and enhanced expression of canalicular ABC transporters involved in phase III of hepatic detoxification. *Toxicology* , **2007**, 232, 24-36	4.4	5
92	Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2359-67	3.4	12
91	Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver-placenta-maternal liver trio. *Journal of Pineal Research*, **2007**, 43, 130-9	10.4	12
90	Inhibition of the intestinal absorption of bile acids using cationic derivatives: mechanism and repercussions. *Biochemical Pharmacology*, **2007**, 73, 394-404	6	14
89	Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases. *Biochemical Pharmacology*, **2007**, 73, 1394-404	6	17
88	Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. *Placenta*, **2007**, 28, 107-17	3.4	97
87	Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3-1 and Can 10. *Cell and Tissue Research*, **2007**, 330, 447-60	4.2	15
86	Effect of cantharidin, cephalotaxine and homoharringtonine on "in vitro" models of hepatitis B virus (HBV) and bovine viral diarrhoea virus (BVDV) replication. *Planta Medica*, **2007**, 73, 552-8	3.1	29
85	Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis. *Journal of Lipid Research*, **2007**, 48, 1362-70	6.3	20
84	Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. *Biochemical Pharmacology*, **2006**, 72, 729-38	6	68
83	Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid. *Placenta*, **2006**, 27, 34-41	3.4	63

82	Antiviral effect of artemisinin from Artemisia annua against a model member of the Flaviviridae family, the bovine viral diarrhoea virus (BVDV). *Planta Medica*, **2006**, 72, 1169-74	3.1	109
81	Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 290, R749-56	3.2	8
80	OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes?. *Journal of Biological Chemistry*, **2006**, 281, 30326-35	5.4	67
79	Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. *Life Sciences*, **2006**, 79, 1014-9	6.8	8
78	Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. *Journal of Hepatology*, **2006**, 44, 1150-7	13.4	100
77	Maternal ethanol consumption during pregnancy enhances bile acid-induced oxidative stress and apoptosis in fetal rat liver. *Toxicology*, **2006**, 225, 183-94	4.4	29
76	Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. *Journal of Hepatology*, **2005**, 43, 324-32	13.4	60
75	Transient changes in the expression pattern of key enzymes for bile acid synthesis during rat liver regeneration. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2005**, 1734, 127-35	5	11
74	Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. *Clinical Science*, **2005**, 109, 199-207	6.5	12
73	Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. *Journal of Gastroenterology and Hepatology (Australia)*, **2005**, 20, 547-54	4	25
72	Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. *Antiviral Research*, **2005**, 68, 75-83	10.8	161
71	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. *Annals of Hepatology*, **2005**, 4, 70-76	3.1	24
70	Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 751-8	4.7	14
69	Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 315, 24-35	4.7	18
68	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. *Annals of Hepatology*, **2005**, 4, 70-6	3.1	7
67	A review on the molecular mechanisms involved in the placental barrier for drugs. *Current Drug Delivery*, **2004**, 1, 275-89	3.2	27
66	Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2004**, 287, R1505-16	3.2	51
65	Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. *Molecular Pharmacology*, **2003**, 63, 742-50	4.3	38

64	Effect of maternal obstructive cholestasis during pregnancy on the biliary transport of horseradish peroxidase in the rat offspring. *Clinical Science*, **2003**, 105, 347-53	6.5	6
63	Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. *Biochemical Journal*, **2003**, 371, 897-905	3.8	145
62	The hepatobiliary-like excretory function of the placenta. A review. *Placenta*, **2003**, 24, 431-8	3.4	36
61	Excretion of foetal bilirubin by the rat placenta-maternal liver tandem. *Placenta*, **2003**, 24, 462-72	3.4	12
60	Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH. *Biochimica Et Biophysica Acta - Biomembranes*, **2003**, 1611, 249-57	3.8	19
59	Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 305, 515-24	4.7	52
58	Physiological characteristics of allo-cholic acid. *Journal of Lipid Research*, **2003**, 44, 84-92	6.3	17
57	Evidence for carrier-mediated transport of unconjugated bilirubin across plasma membrane vesicles from human placental trophoblast. *Placenta*, **2002**, 23, 527-35	3.4	39
56	Chronic renal failure-induced changes in serum and urine bile acid profiles. *Digestive Diseases and Sciences*, **2002**, 47, 2398-406	4	34
55	Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. *Molecular Pharmacology*, **2002**, 61, 853-60	4.3	120
54	Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in vitro replicative system. *Antiviral Chemistry and Chemotherapy*, **2002**, 13, 371-80	3.5	8
53	Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis. *Clinical Science*, **2002**, 102, 143	6.5	10
52	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. *Clinical Science*, **2002**, 102, 587-593	6.5	37
51	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. *Clinical Science*, **2002**, 102, 587	6.5	19
50	Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. *Journal of Hepatology*, **2002**, 36, 534-42	13.4	38
49	Relationship between tumor cell load and sensitivity to the cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2. *Journal of Drug Targeting*, **2002**, 10, 397-404	5.4	7
48	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. *Clinical Science*, **2002**, 102, 587-93	6.5	14
47	Predominance of human versus rat phenotype in the metabolic pathways for bile acid synthesis by hybrid WIF-B9 cells. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2001**, 1534, 45-55	5	12

46	Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity. *Journal of Drug Targeting*, **2001**, 9, 185-200	5.4	16
45	Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. *Clinical Science*, **2001**, 100, 499-508	6.5	8
44	Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. *Clinical Science*, **2001**, 100, 499	6.5	24
43	Overcoming cisplatin resistance in vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2. *International Journal of Cancer*, **2000**, 88, 287-292	7.5	26
42	Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem. *Hepatology*, **2000**, 31, 975-83	11.2	46
41	Structural characterization, kinetic studies, and in vitro biological activity of new cis-diamminebis-cholylglycinate(O,O') Pt(II) and cis-diamminebis-ursodeoxycholate(O,O') Pt(II) complexes. *Bioconjugate Chemistry*, **2000**, 11, 167-74	6.3	33
40	Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2000**, 1500, 153-60	6.9	43
39	Bile acid secretion during rat liver carcinogenesis. *Life Sciences*, **2000**, 66, 1085-95	6.8	14
38	Overcoming cisplatin resistance in vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2 **2000**, 88, 287		1
37	Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. *Gut*, **1999**, 45, 446-52	19.2	51
36	Synthesis and characterization of sodium cis-dichlorochenodeoxycholylglycinato(O,N) platinum(II)--cytostatic activity. *BioMetals*, **1999**, 12, 281-8	3.4	10
35	Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). *Journal of Controlled Release*, **1999**, 57, 161-9	11.7	17
34	Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. *Journal of Hepatology*, **1999**, 31, 521-8	13.4	38
33	DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. *International Journal of Cancer*, **1998**, 78, 346-52	7.5	26
32	Fetal excretion of the fluorescent bile acid derivative cholylglycylamido-fluorescein (FITC-GC) by the rat placenta-maternal liver tandem. *Placenta*, **1998**, 19, 119-26	3.4	8
31	Transient enterohepatic circulation and enhanced biliary versus urinary excretion of the cytostatic drug bischolylglycinate-chloroplatinum(II) (Bamet-H2). *International Journal of Pharmaceutics*, **1998**, 172, 79-88	6.5	3
30	Enhanced bile formation induced by experimental dicrocoeliosis in the hamster. *Life Sciences*, **1998**, 63, 1963-74	6.8	3
29	Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. *Journal of Hepatology*, **1998**, 28, 829-39	13.4	93

28	Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II). *Journal of Hepatology*, **1998**, 28, 417-25	13.4	18
27	Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. *Journal of Lipid Research* , **1998**, 39, 1792-1798	6.3	19
26	In vitro test to determine the effect of cytostatic drugs on co-cultured rat hepatocytes and hepatoma cells. *International Journal of Experimental Pathology*, **1998**, 79, 109-115	2.8	2
25	Synthesis and characterization of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate. *Bioconjugate Chemistry*, **1997**, 8, 453-8	6.3	36
24	Bile acid secretion during synchronized rat liver regeneration. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1997**, 1362, 56-66	6.9	21
23	Effect of bile acids on hepatobiliary transport of cisplatin by perfused rat liver. *Basic and Clinical Pharmacology and Toxicology*, **1997**, 80, 111-7		2
22	Bile secretion by the rat liver during synchronized regeneration. *International Journal of Experimental Pathology*, **1997**, 78, 109-16	2.8	12
21	Effect of maternal cholestasis on biliary lipid and bile acid secretion in the infant rat. *Hepatology*, **1997**, 26, 527-36	11.2	16
20	Effect of maternal cholestasis on the kinetics of bile acid transport across the canalicular membrane of infant rat livers. *International Journal of Experimental Pathology*, **1997**, 78, 383-90	2.8	5
19	Evidence for dual effect of bile acids on thymidine anabolism and catabolism by the regenerating rat liver. *Biochimica Et Biophysica Acta - General Subjects*, **1996**, 1289, 136-44	4	2
18	Role of rate-limiting enzymes of nucleotide metabolism in taurocholate-induced DNA synthesis inhibition. *Journal of Hepatology*, **1996**, 25, 191-9	13.4	5
17	Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. *Hepatology*, **1996**, 23, 1208-17	11.2	38
16	Relationship between bile acid transplacental gradients and transport across the fetal-facing plasma membrane of the human trophoblast. *Pediatric Research*, **1995**, 38, 156-63	3.2	31
15	Influence of hydroxylation and conjugation in cross-inhibition of bile acid transport across the human trophoblast basal membrane. *Biochimica Et Biophysica Acta - Biomembranes*, **1993**, 1151, 28-34	3.8	11
14	Effect of insulin and glucose load on bile lactate secretion by the isolated rat liver. Role of hepatic parenchyma heterogeneity. *Biochimica Et Biophysica Acta - General Subjects*, **1993**, 1158, 8-14	4	
13	Bile acid□induced modifications in DNA synthesis by the regenerating perfused rat liver. *Hepatology* , **1993**, 18, 1182-1192	11.2	16
12	Substrate-specific differences in the rate of bile acid carrier reorientation: studies on human placental basal vesicles. *Biochimica Et Biophysica Acta - Biomembranes*, **1992**, 1111, 139-41	3.8	
11	Hyperglycemia-induced cholestasis in the isolated perfused rat liver. *Hepatology*, **1991**, 14, 184-91	11.2	16

10	Plasma membrane-bound carbonic anhydrase activity in the regenerating rat liver. *Biochimica Et Biophysica Acta - Biomembranes*, **1991**, 1061, 9-14	3.8	7
9	Bile acid transport by basal membrane vesicles of human term placental trophoblast. *Gastroenterology*, **1990**, 99, 1431-8	13.3	46
8	Influence of backward perfusion on ursodeoxycholate-induced choleresis in isolated in situ rat liver. *Journal of Hepatology*, **1990**, 11, 165-71	13.4	35
7	Effect of streptozotocin-induced diabetes on sex differences in biliary lipid secretion in the rat. *Lipids and Lipid Metabolism*, **1990**, 1043, 106-12		6
6	Diabetes-induced cholestasis in the rat: possible role of hyperglycemia and hypoinsulinemia. *Hepatology*, **1988**, 8, 332-40	11.2	33
5	Evidence for the presence of carbonic anhydrase in the plasma membrane of rat hepatocytes. *Biochimica Et Biophysica Acta - Biomembranes*, **1988**, 945, 17-22	3.8	14
4	Influence of dehydrocholate on bilirubin transport into bile in the rat. *Digestion*, **1986**, 33, 80-8	3.6	6
3	Use of thermal fogs of bioresmethrin and cismethrin for control of Periplaneta americana (Insecta: Blattidae) in sewers. *Journal of Medical Entomology*, **1977**, 13, 625-6	2.2	6
2	Unmet needs in basic and translational research in Cholangiocarcinoma. *Liver Cancer International*,	0.8	
1	Genetic Variants Involved in Intracellular Mechanisms of Chemoresistance to Anticancer Drugs Due to Changes in the Effect on Their Molecular Targets		1